CSPC Pharmaceutical Group Unveils 2023 Innovation Highlights and Submits IPO Prospectus for CSPC Innovation

Mar 22, 2024 18:03 CST Updated 18:03

CSPC

Innovative Drug Research and Development, Manufacturer

Simnova

Innovative Cell Therapy Product Developer

E.N.D

Previous article recommendations:

General Office of the State Council Issues Important Action Plan

JW Therapeutics' CAR-T Product "Relmacabtagene Autoleucel" Achieves Sales of 174 Million Yuan in 2023

Progress in Organoid Technology and Industry

New Developments in Nearly 100 Million Yuan Fraud Case Against Leading CDMO Company: Actual Controller Has Paid Nearly 90 Million Yuan Which Has Been Received

【Document Download】GMP Quality System for Key Raw Materials in CGT

Accelerating the Launch of Rare Disease Drugs | Bendgene and Shanghai Pharma Real Reach Strategic Cooperation

A Cell Therapy Company Goes Public

The State Council Issues Significant Document, Strongly Supporting the Development of Five Types of Pharmaceutical Enterprises, Involving New Drug Development and Industrialization in Cell Therapy and Gene Therapy

The State Council Revises the "Regulations on the Administration of Human Genetic Resources," New Rules to Take Effect on May 1, 2024

Investment of nearly 1 billion yuan, construction area of approximately 150,000 square meters, focusing on cell therapy, gene therapy, and vaccine industries... ...

Simnova Completes RMB 200 Million A+ Round Financing

TOP10 Pharmaceutical Companies Ranking Released, All Have Layout in Cell and Gene Therapy

CAR-T Therapy from CARsgen Pharma Debuts at 1.15 Million Yuan, with Expected Annual Sales Peak Exceeding 1 Billion Yuan

Two National Scientific Research Platforms Approved and Established by Subsidiaries of China National Pharmaceutical Group's CNBG Officially Unveiled

TIL Cell Therapy Priced at 3.7 Million Shows Promising Market Potential, with First-Quarter Sales Expected to Exceed 30 Million

Fosun Pharma Subsidiary's NK Cell Therapy GCK-01 Approved for Clinical Trials

First in China, Yaotang Biotech's In Vivo Gene Editing Drug YOLT-201 Approved for Clinical Trials

Guangdong Province Releases New Policy! Key Focus on Five Major Projects: Gene Technology, Cell Therapy, AI + Biomedicine, and Synthetic Biology

Covering an area of approximately 13,000 square meters, the Simnova Cell Therapy Drug Industrialization Base Project has been launched.

Another Global Strategic Center of a Pharmaceutical Giant Settles in Shanghai, to Establish Shanghai as an Important R&D Base in the Field of Cell Therapy

The First AAV Gene Therapy for Hemophilia A Fell Far Short of Sales Expectations Last Year

Xiong'an Officially Issues! Support for the Development of Modern Life Sciences and Biotechnology Industries such as Cell Therapy, Genetic Engineering, and Tissue Engineering

Government Invests 6 Billion Yuan to Fund the Establishment of a Life Health Research Institute, Focusing on Cutting-edge Topics like Cell and Gene Therapy

Statement:The content is sourced from CSPC. This article aims to share knowledge, all content is for reference only and does not constitute any recommendations.